Table of Contents 1 Relevant Concepts of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 1.1 Indications for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor 1.2 Development of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China 1.3 Governmental Approval of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China 1.4 The Impact of COVID-19 on Pegylated Recombinant Human Granulocyte Colony Stimulating Factor sales in China 2 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2016-2020 2.1 Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor 2.1.1 Overall Sales Value 2.1.2 Sales Value by Regions 2.2 Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor 2.2.1 Overall Sales Volume 2.2.2 Sales Volume by Regions 2.3 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Dosage Form in China, 2016-2020 2.3.1 Injection 2.3.2 Analysis of Other Dosage Forms 3 Analysis of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020 3.1 Analysis of Market Share of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers 3.1.1 Investigation on Market Share by Sales Value 3.1.2 Investigation on Market Share by Sales Volume 3.2 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. 3.2.1 Enterprise Profile 3.2.2 Sales of Jinyouli (Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China 3.3 Qilu Pharmaceutical Co., Ltd. 3.3.1 Enterprise Profile 3.3.2 Sales of Xinruibai (Qilu Pharmaceutical Co., Ltd.'s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China 4 Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor for Different Manufacturers in China, 2020-2021 4.1 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. (Yinish) 4.2 Qilu Pharmaceutical Co., Ltd. (Xinruibai) 5 Prospect of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market, 2021-2025 5.1 Influential Factors of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Development 5.1.1 The Impact of COVID-19 on Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market 5.1.2 Market Drivers and Opportunities 5.1.3 Market Threats and Challenges 5.2 Forecast on Market Size 5.3 Forecast on Market Trend List of Charts Chart Patent Information About Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection Registration in China Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection over the World Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020 Chart Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020 Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China, 2016-2020 Chart Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Injection in China by Regions, 2016-2020 Chart Market Share by Sales Value of Top Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020 Chart Sales Value and Volume of Yinish in China, 2016-2020 Chart Sales Value and Volume of Xinruibai in China, 2016-2020 Chart Referential Prices of Yinish in China by Regions, 2020-2021 Chart Referential Prices of Xinruibai in China by Regions, 2020-2021 Chart Forecast on Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025 Chart Forecast on Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2021-2025